Home › Funds › Citigroup Inc › SABS
Citigroup Inc position in SABS
SAB BIOTHERAPEUTICS INC · Health Care
Latest position (Q2 2026)26.58K sh
Reported value held$103.68K
Portfolio Weight0.00%
First reportedQ4 2021
Last changeReduce
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2021 | 1.29K | $10.00K | New |
| Q1 2022 | 7.02K | $26.00K | Add |
| Q2 2022 | 639 | $1.00K | Reduce |
| Q3 2022 | 494 | $0 | Reduce |
| Q3 2025 | 832 | $1.67K | New |
| Q4 2025 | 29.97K | $112.10K | Add |
| Q1 2026 | 36.80K | $140.96K | Add |
| Q2 2026 | 26.58K | $103.68K | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding SABS
- Balyasny Asset Management 3.76M sh · $14.67M · Q2 2026
- BlackRock Inc 3.07M sh · $11.96M · Q2 2026
- Millennium Management 2.75M sh · $10.72M · Q2 2026
- Vanguard Group 1.85M sh · $6.91M · Q4 2025
- Geode Capital Management 1.28M sh · $4.98M · Q2 2026
- UBS Group AG 365.88K sh · $1.43M · Q2 2026
- Northern Trust Corp 362.49K sh · $1.41M · Q2 2026
- Two Sigma Investments 214.63K sh · $837.07K · Q2 2026
- Goldman Sachs Group 191.31K sh · $746.09K · Q2 2026
- Citadel Advisors 143.80K sh · $560.81K · Q2 2026
- BNY Mellon 107.85K sh · $420.60K · Q2 2026
- Charles Schwab Investment Management 105.68K sh · $412.16K · Q2 2026